Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Total Debt: 2022-2024

Historic Total Debt for UroGen Pharma (URGN) over the last 3 years, with Dec 2024 value amounting to $121.7 million.

  • UroGen Pharma's Total Debt rose 0.33% to $122.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $122.1 million, marking a year-over-year increase of 0.33%. This contributed to the annual value of $121.7 million for FY2024, which is 23.52% up from last year.
  • Latest data reveals that UroGen Pharma reported Total Debt of $121.7 million as of FY2024, which was up 23.52% from $98.6 million recorded in FY2023.
  • In the past 5 years, UroGen Pharma's Total Debt registered a high of $121.7 million during FY2024, and its lowest value of $97.5 million during FY2022.
  • Its 3-year average for Total Debt is $105.9 million, with a median of $98.6 million in 2023.
  • Data for UroGen Pharma's Total Debt shows a peak YoY climbed of 23.52% (in 2024) over the last 5 years.
  • UroGen Pharma's Total Debt (Yearly) stood at $97.5 million in 2022, then climbed by 1.04% to $98.6 million in 2023, then rose by 23.52% to $121.7 million in 2024.